Condition
Cutaneous Polyarteritis Nodosa
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
6 treatments under study, led by Dapsone
Research Leaders
5 sponsors active, led by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Related Conditions
Often studied with 10 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Terminated1
Recruiting1
Clinical Trials (2)
Research Network
Common Treatments
- Dapsone1
- Infliximab1
- Azathioprine1
- Rituximab1
- Tocilizumab1
Active Sponsors
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)1
- Cambridge University Hospitals NHS Foundation Trust1
- National Center for Advancing Translational Sciences (NCATS)1
- Office of Rare Diseases (ORD)1
- University of Pennsylvania1
Top Investigators
Cambridge University Hospitals NHS Foundation Trust/University of Cambridge
University of Pennsylvania
University of Toronto/Mount Sinai Hospital
Related Conditions
- Iga Vasculitis2
- Cogan Syndrome1
- Primary Cutaneous Vasculitis1
- Henochschönlein Purpura1
- Primary Angiitis Of Central Nervous System1